trial

A Study to Evaluate the Overall Effects of Treatment With Abbreviated CT-156 in People With Schizophrenia

NCTId NCT06136936
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 53 (actual)
Sponsored by Click Therapeutics, Inc.
Primary completion 2024-01-18
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
53 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Single
Start
2023-09-20
Primary completion
2024-01-18
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
CT-156-C-001

Sponsors

Click Therapeutics, Inc.Lead Sponsor
Boehringer IngelheimCollaborator

Investigators

1
Shaheen LakhanStudy Director

Sites

1 total
New York, United States

Facts & assertions

4 sourced
Enrollment
53
Phase
NA
Primary Completion Date
2024-01-18
Status
COMPLETED
relationships
The graph out of here
drug
CT-156-C-001
drug
lead_sponsor
Click Therapeutics, Inc.
company
collaborator
Boehringer Ingelheim
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Shaheen Lakhan
person